摘要： 目的 基于癌症基因组图谱（TCGA）数据库，应用生物信息学方法分析N6-甲基腺苷（m⁶A） RNA甲基化调节因子（以下简称m⁶A调节因子）在前列腺癌进展过程中的分子特征及临床意义。方法 基于13种m⁶A调节因子对前列腺癌数据进行分析，以识别不同亚群，并进行差异表达分析。基于差异基因构建LASSO Cox回归模型，并绘制Kaplan-Meier生存曲线和受试者操作特征曲线，计算曲线下面积，以判断模型预测性能。对关键因子进行免疫浸润分析。结果 基于13种m⁶A调节因子识别出与前列腺癌发生密切相关的亚群。获得由6种m⁶A调节因子（OAS3、MYOF、SMIM22、SNORD60、ROMO1、MRPL41）构建的风险模型。ROMO1在前列腺癌中表达水平较高，并与CD8⁺T细胞的免疫浸润相关性强。结论 m⁶A调节因子的表达与前列腺癌的临床病理特征高度相关。ROMO1在前列腺癌中高表达，有望作为独立预测前列腺癌预后的生物标志物，为基于mRNA的表观遗传修饰角度理解和探索前列腺癌的早期诊断和临床治疗提供了线索。

综合分析和鉴定m⁶A RNA甲基化调节因子对前列腺癌进展及预后的影响

张乐¹, 宁静华¹, 张鑫¹, 王振¹, 刘虹汝¹, 张钰哲^1,2,3

1. 大理大学基础医学院病理学与病理生理学教研室, 云南 大理 671000;
2. 云南抗病原药用植物筛选重点实验室, 云南 大理 671000;
3. 云南省昆虫生物医药重点实验室, 云南 大理 671000

收稿日期:2022-12-31出版日期:2023-11-30发布日期:2023-11-07
通讯作者:张钰哲E-mail:lzuzyz1568@hotmail.com
作者简介:张乐(1996-),女,硕士研究生.
基金资助:云南省地方本科高校（部分）基础研究联合专项面上项目（202001BA070001-064，202101BA070001-102）；云南省昆虫生物医药研发重点实验室开放课题立项项目（AP2022016）；大理大学博士科研启动费立项项目（KYBS2018012）


关键词: m⁶A, 前列腺癌, 癌症基因组图谱, 甲基化修饰, ROMO1
Abstract: Objective To analyze N6-methyladenosine (m⁶A) RNA methylation regulators using data from The Cancer Genome Atlas (TCGA) and explore the molecular characteristics and clinical significance of m⁶A regulators in prostate cancer progression. Methods Prostate cancer data were analyzed with respect to 13 m⁶A regulators to identify different subgroups and perform differential expression analyses. The LASSO Cox regression model was constructed based on the differentially expressed genes. Kaplan-Meier survival curves and receiver operator characteristic curves were drawn. The area under the curve was calculated to determine the predictive performance of the model. Key factors were analyzed based on immune infiltration. Results Based on the 13 m⁶A regulators, subgroups closely associated with prostate cancer development were identified, and a risk model was constructed using six m⁶A regulatorys (OAS3, MYOF, SMIM22, SNORD60, ROMO1, and MRPL41). ROMO1 is highly expressed in prostate cancer and is strongly correlated with the immune infiltration of CD8⁺T cells. Conclusion The results of this study show that the expression of m⁶A regulators is highly correlated with the clinicopathological features of prostate cancer. ROMO1 may serve as an independent biomarker to predict the prognosis of prostate cancer. The high expression of ROMO1 in prostate cancer provides clues for understanding and exploring the early diagnosis and clinical treatment of prostate cancer from the perspective of epigenetic modification of mRNA.
Key words: m⁶A, prostate cancer, The Cancer Genome Atlas, methylation modification, ROMO1
PDF全文下载地址:

https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=3310